Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term phase-iii trial. Found 33 abstracts

no pagination
Shaikh T, Meyer JE, Horwitz EM. Optimal Use of Combined Modality Therapy in the Treatment of Esophageal Cancer. Surg Oncol Clin N Am. 2017 Jul;26(3):405-29.   PMCID: REVIEW
Agarwal N, Bellmunt J, Maughan BL, Boucher KM, Choueiri TK, Qu AQ, Vogelzang NJ, Fougeray R, Niegisch G, Albers P, Wong YN, Ko YJ, Sridhar SS, Tantravahi SK, Galsky MD, Petrylak DP, Vaishampayan UN, Mehta AN, Beer TM, Sternberg CN, Rosenberg JE, Sonpavde G. Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer. 2014 Apr;12(2):130-7.   PMCID: Pmc4142680
Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA. Ovarian Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network. 2012 Nov;10(11):1339-49.
Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY, Horwitz EM, Hanks GE, Price RA, Pollack A. RADIOTHERAPY DOSES OF 80 GY AND HIGHER ARE ASSOCIATED WITH LOWER MORTALITY IN MEN WITH GLEASON SCORE 8 TO 10 PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2012 Apr;82(5):1949-56.   PMCID: PMC3827957
Rodgers GM, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB. Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network. 2012 May;10(5):628-+.   PMCID: not NIH funded
Stehman FB, Brady MF, Thigpen JT, Rossi EC, Burger RA. Cytokine use and survival in the first-line treatment of ovarian cancer: A Gynecologic Oncology Group Study. Gynecologic Oncology. 2012 Dec;127(3):495-501.   PMCID: PMC3496007
Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK. Long-Term Survival After Radical Prostatectomy Versus External-Beam Radiotherapy for Patients With High-Risk Prostate Cancer. Cancer. 2011 Jul;117(3):2883-91.   PMCID: PMC3139725
Carlson RW, Allred C, Anderson BO, Burstein HJ, Carter WB, Edge SB, Erban JK, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Sachdev J, Smith ML, Somlo G, Ward JH, Wolff AC, Zellars R. Invasive Breast Cancer. Journal of the National Comprehensive Cancer Network. 2011 Feb;9(2):136-222.   PMCID: not NIH funded - practice guideline
Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. OLDER AGE PREDICTS DECREASED METASTASIS AND PROSTATE CANCER-SPECIFIC DEATH FOR MEN TREATED WITH RADIATION THERAPY: META-ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1293-301.   PMCID: NIHMS285956
Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC. Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network. 2011 Oct;9(10):1086-113.   PMCID: not NIH funded
Klayton TL, Ruth K, Horwitz EM, Uzzo RG, Kutikov A, Chen DY, Sobczak M, Buyyounouski MK. Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer. Radiotherapy and Oncology. 2011 Dec;101(3):508-12.   PMCID: PMC3225561
Plimack ER, Hudes GR. Selecting Targeted Therapies for Patients With Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network. 2011 Sep;9(9):997-1007.   PMCID: not NIH funded
Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP PROSTATE CLINICAL TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):445-52.   PMCID: PMC2952349
Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, Goldsmith BJ, Horwitz EM, Ibbott GS, Lee WR, Nag S, Suh WW, Potters L. AMERICAN SOCIETY FOR RADIATION ONCOLOGY (ASTRO) AND AMERICAN COLLEGE OF RADIOLOGY (ACR) PRACTICE GUIDELINE FOR THE TRANSPERINEAL PERMANENT BRACHYTHERAPY OF PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Feb;79(2):335-41.   PMCID: PMCID: PMC3030655 [Available on 2012/2/1]
Sharma NK, Li TY, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):437-44.   PMCID: PMC2909627
Negin BP, Cohen SJ. Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges. Current treatment options in oncology. 2010 Jun;11(1-2):1-13.   PMCID: not NIH funded
Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Dec;78(5):1314-22.   PMCID: PMCID: PMC2920356 [Available on 2011/12/1]
Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW, Malafa MP, Muscarella P, Nakakura EK, Sasson AR, Thayer SP, Tyler DS. Pancreatic Adenocarcinoma. Journal of the National Comprehensive Cancer Network. 2010 Sep;8(9):972-+.   PMCID: PMC3135380
Zbrozek AS, Hudes G, Levy D, Strahs A, Berkenblit A, DeMarinis R, Parasuraman S. Q-TWiST Analysis of Patients Receiving Temsirolimus or Interferon Alpha for Treatment of Advanced Renal Cell Carcinoma. PharmacoEconomics. 2010 Jan;28(7):577-84.   PMCID: not NIH funded
Akino T, Hida K, Hida Y, Tsuchiya K, Freedman D, Muraki C, Ohga N, Matsuda K, Akiyama K, Harabayashi T, Shinohara N, Nonomura K, Klagsbrun M, Shindoh M. Cytogenetic Abnormalities of Tumor-Associated Endothelial Cells in Human Malignant Tumors. American Journal of Pathology. 2009 Dec;175(6):2657-67.   PMCID: PMC2789618
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term phase-iii trial

phase-iii trial chemotherapy neoadjuvant Prostate cancer therapy NCCN Clinical Practice Guidelines competing risk NCCN Guidelines breast-cancer randomized controlled-trial biochemical failure carcinoma group protocol 92-02 radical prostatectomy radiation adjuvant gemcitabine long-term survival placebo-controlled trial risk Clinical trials randomized-trial intensity-modulated radiotherapy androgen suppression external-beam radiation radiation-therapy Prognostic factors quality-of-life hormonal-therapy locally advanced-carcinoma cooperative-oncology-group Radiation therapy conformal radiation-therapy competing bevacizumab androgen deprivation radiotherapy suppression time trends disease-free survival definitive radiotherapy squamous-cell carcinoma Brachytherapy Age factors drug hypersensitivity interobserver variability surgical Prostate kidney-disease Overall survival prophylactic cranial irradiation genes Dosimetry seed implantation randomized trial External beam radiation therapy in-situ hybridization colony-stimulating factor Advanced urothelial carcinoma carcinoma-cells Radiation daily thoracic radiotherapy growth portal-vein confluence hypogonadal men radical prostatectomy prostate cancer-radiation therapy-androgen-deprivation therapy-prostate-specific antigen fallopian-tube renal cell esophageal cancer adverse drug events bladder-cancer pancreas collecting duct carcinoma predict pathological stage high-grade dysplasia extended retroperitoneal lymphadenectomy cervical-cancer Serum testosterone cisplatin plus neuroendocrine tumors forthcoming 7th edition progenitor cells advanced-stage ovarian blood-product support surgical adjuvant Metastasis ultrasonography small antigen era double-blind preoperative biliary drainage messenger-rna Outcomes multicenter randomized-trial platinum-containing cancer patients trimodality active chemotherapy carboplatin stroma anemia adenocarcinoma clinical-significance Progression-free survival at 6 months antigen interleukin-2 gleason score pegylated liposomal doxorubicin quality-adjusted survival Conformal erythropoiesis-stimulating agents tract mastectomy deprivation therapy hypersensitivity reactions greater-than-20 aplasia 1975 cock sj-biometrics-v31-p103 etoposide kidney neoplasms Cytokines Erythropoietin-Ovarian cancer positron-emission-tomography Second-line treatment pathology 1st-line treatment Carcinoma interstitial brachytherapy cell ductal carcinoma in situ immunomagnetic enrichment predicting recurrence hematopoietic stem 2010 dermott df-v28 sentinel-node biopsy sunitinib defining biochemical failure ductal carcinoma peripheral-blood endoscopic retrograde vinflunine hypersensitivity Safety in-hospital mortality ml breast cancer metaanalysis Hormonal ablation ng primary transitional-cell carcinoma
Last updated on Friday, January 03, 2020